Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer
نویسندگان
چکیده
منابع مشابه
Targeting eNOS in pancreatic cancer.
Mortality from pancreatic ductal adenocarcinoma cancer (PDAC) is among the highest of any cancer and frontline therapy has changed little in years. Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS III) has been implicated recently in the pathogenesis of PDACs. In this study, we used genetically engineered mouse and human xenograft models to evaluate the consequences of target...
متن کاملNAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians
NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyses the reduction of quinoid compounds to hydroquinones, preventing the generation of free radicals and reactive oxygen. A "C" to "T" transversion at position 609 of NQO1, leading to a nonsynonymous amino acid change (Pro187Ser, P187S), results in an altered enzyme activity. No NQO1 protein activity was detected in NQO1(609)TT genotype, and low to i...
متن کاملTargeting Pancreatic Cancer Stem Cells
Carcinomas of an epithelial-origin account for the majority of all malignant cancers worldwide. As the most common pancreatic cancer, Pancreatic Ductal Adeno Carcinoma (PDAC) is a carcinoma with an extremely high lethality [1-3]. Compared to other cancers originating in the digestive system, the therapeutic outcome of PDAC treatment is the least promising, largely resulting from a lack of sympt...
متن کاملTargeting metabolic scavenging in pancreatic cancer.
Pancreatic tumor metabolism is rewired to facilitate survival and growth in a nutrient-depleted environment. This leads to a unique dependence on metabolic recycling and scavenging pathways, including NAD salvage. Targeting this pathway in pancreatic cancer disrupts metabolic homeostasis and impairs tumor growth.
متن کاملTargeting apoptosis pathways in pancreatic cancer.
Pancreatic cancer - here in particular pancreatic ductal adenocarcinoma (PDAC) - is still a highly therapy refractory disease. Amongst the mechanisms by which PDAC cells could escape any non-surgical therapy, anti-apoptotic protection seems to be the most relevant one. PDAC cells have acquired resistance to apoptotic stimuli such as death ligands (FasL, TRAIL) or anti-cancer drugs (gemcitabine)...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Carcinogenesis
سال: 2005
ISSN: 0899-1987,1098-2744
DOI: 10.1002/mc.20107